Pilot In Vivo Evaluation of a Resorbable, Antibiotic-Eluting Bone Void Filler to Prevent Periprosthetic Joint Infection

摘要

The novel resorbable, antibiotic eluting bone void filler appears to possess both osteoconductive and bactericidal properties. In previous in vitro studies, the AEBVF has shown the ability to elute antibiotic for up to 7 weeks at bactericidal concentrations. Significant degradation was also observed in vitro. Consistent with these findings, these data show the ability to 1) eliminate a periprosthetic S. aureus burden of 10~5 colony forming units, 2) promote bone remodeling superior to a known bone void filler, and 3) degrade at a rate that does not interfere with host bone remodeling. Evaluation of the histology and histomorphometry data is ongoing.